

1627

J. Baschoff

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/482,585

DATE: 03/16/2001
TIME: 15:21:09

Input Set : A:\Su931011.app
Output Set: N:\CRF3\03162001\I482585.raw

ENTERED

#8

3 <110> APPLICANT: Hangauer Jr., David G.
 4 Marsilje, Thomas H.
 5 Milkiewicz, Karen L.
 7 <120> TITLE OF INVENTION: A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS
 9 <130> FILE REFERENCE: 19226/931
 11 <140> CURRENT APPLICATION NUMBER: 09/482,585
 12 <141> CURRENT FILING DATE: 2000-01-13
 14 <150> PRIOR APPLICATION NUMBER: 60/115,643
 15 <151> PRIOR FILING DATE: 1999-01-13
 17 <160> NUMBER OF SEQ ID NOS: 6
 19 <170> SOFTWARE: PatentIn Ver. 2.1
 21 <210> SEQ ID NO: 1
 22 <211> LENGTH: 5
 23 <212> TYPE: PRT
 24 <213> ORGANISM: Artificial Sequence
 26 <220> FEATURE:
 27 <223> OTHER INFORMATION: Description of Artificial Sequence: src substrate
 28 pentapeptide
 30 <400> SEQUENCE: 1
 31 Ile Tyr Gly Glu Phe
 32 1 5
 35 <210> SEQ ID NO: 2
 36 <211> LENGTH: 5
 37 <212> TYPE: PRT
 38 <213> ORGANISM: Artificial Sequence
 40 <220> FEATURE:
 41 <221> NAME/KEY: PEPTIDE
 42 <222> LOCATION: (2)
 43 <223> OTHER INFORMATION: Xaa in position 2 is modified Tyr.
 45 <220> FEATURE:
 46 <223> OTHER INFORMATION: Description of Artificial Sequence: src
 47 pentapeptide scaffold
 49 <400> SEQUENCE: 2
 50 Ile Xaa Gly Glu Phe
 51 1 5
 54 <210> SEQ ID NO: 3
 55 <211> LENGTH: 5
 56 <212> TYPE: PRT
 57 <213> ORGANISM: Artificial Sequence
 59 <220> FEATURE:
 60 <221> NAME/KEY: PEPTIDE
 61 <222> LOCATION: (4)
 62 <223> OTHER INFORMATION: Xaa in position 4 is modified Ala.
 64 <220> FEATURE:
 65 <223> OTHER INFORMATION: Description of Artificial Sequence: PKA
 66 pentapeptide scaffold
 68 <400> SEQUENCE: 3

RECEIVED

MAR 23 2001

TECH CENTER 1600/2900

3/16/01

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/482,585

DATE: 03/16/2001
TIME: 15:21:09

Input Set : A:\Su931011.app
Output Set: N:\CRF3\03162001\I482585.raw

OK 69 Arg Arg Gly Xaa Ile
70 1 5
73 <210> SEQ ID NO: 4
74 <211> LENGTH: 5
75 <212> TYPE: PRT
76 <213> ORGANISM: Artificial Sequence
78 <220> FEATURE:
79 <221> NAME/KEY: PEPTIDE
80 <222> LOCATION: (4)
81 <223> OTHER INFORMATION: Xaa in position 4 is Ala or modified Ala.
83 <220> FEATURE:
84 <223> OTHER INFORMATION: Description of Artificial Sequence: Boronic
85 acid-containing PKA inhibitor
87 <400> SEQUENCE: 4
OK 88 Arg Arg Gly Xaa Ile
89 1 5
92 <210> SEQ ID NO: 5
93 <211> LENGTH: 7
94 <212> TYPE: PRT
95 <213> ORGANISM: Artificial Sequence
97 <220> FEATURE:
98 <223> OTHER INFORMATION: Description of Artificial Sequence: Kemptamide
100 <400> SEQUENCE: 5
101 Leu Arg Arg Ala Ser Leu Gly
102 1 5
105 <210> SEQ ID NO: 6
106 <211> LENGTH: 7
107 <212> TYPE: PRT
108 <213> ORGANISM: Artificial Sequence
110 <220> FEATURE:
111 <221> NAME/KEY: MOD_RES
112 <222> LOCATION: (5)
113 <223> OTHER INFORMATION: Xaa in position 5 is ALA; PHOSPHORYLATION
115 <220> FEATURE:
116 <223> OTHER INFORMATION: Description of Artificial Sequence: Phosphorylated
117 Kemptamide
119 <400> SEQUENCE: 6
OK 120 Leu Arg Arg Ala Xaa Leu Gly
121 1 5

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/482,585

DATE: 03/16/2001
TIME: 15:21:10

Input Set : A:\Su931011.app
Output Set: N:\CRF3\03162001\I482585.raw

L:50 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:69 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:88 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:120 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6